Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Date:11/8/2012

DUBLIN, Nov. 8, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2012.  These results reflect the first full quarter of operations following completion of the EUSA Pharma acquisition in June.  The company also reported the results of its women's health business, which was sold in October, as discontinued operations.

"During the third quarter, we completed the integration of EUSA Pharma's U.S. commercial business, and our R&D group is working to coordinate worldwide Erwinaze® and Asparec® development activities," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "I am very pleased that we have been able to complete two important acquisitions and a divestiture of our non-core women's health business this year, while continuing to deliver solid results fueled by growing sales of key products."

Third quarter 2012 adjusted income from continuing operations, which excluded contributions from the discontinued women's health business, was $78.6 million, or $1.29 per diluted share.  Adjusted income for the discontinued women's health business was $3.0 million, or $0.05 per diluted share, for a total of $1.34 per share on a combined basis. 

GAAP income from continuing operations for the third quarter of 2012 was $33.6 million, or $0.56 per diluted share, and GAAP loss from the discontinued women's health business was $0.4 million, or $0.01 per diluted share.  GAAP net income for the third quarter of 2012 was $33.2 million, or $0.55 per diluted share.

GAAP net income was impacted by various acquisition-related expenses, which included transaction, integration and restructuring expenses, as well as certain non-cash expenses.  A reconciliation of certain GAAP to non-GAAP adjusted information is included with this press release.

Revenues and Product SalesTotal revenues for the quarter ended September 30, 2012 were $175.5 million, including net sales, royalties and contract revenues, but excluding the $8.1 million of net sales attributable to the divested women's health business that were reported separately as discontinued operations.  

A significant increase in total net sales for the third quarter of 2012 over the prior year third quarter resulted from the addition of net sales from the expanded product portfolio acquired in the Azur Pharma and EUSA Pharma transactions, as well as continued growth in net sales of Xyrem® (sodium oxybate) oral solution.Net sales from continuing operations for the third quarter of 2012 included:

  • Xyrem:  Net sales of Xyrem increased by 64% to $102.6 million for the third quarter of 2012, compared to net sales of $62.5 million in the third quarter of 2011. During the third quarter of 2012, the average number of active Xyrem patients was approximately 10,200.
  • Erwinaze/Erwinase: Worldwide net sales of Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi) were $31.7 million.  Erwinaze was approved by the U.S. FDA in November 2011.
  • Prialt:  Third quarter 2012 net sales of Prialt® (ziconotide) intrathecal infusion were $5.4 million, compared to $5.0 million in the prior year quarter on a pro forma basis.
  • Psychiatry Products:  Net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD, were $21.0 million for the third quarter of 2012.  Net sales of these products in the prior year quarter were $19.7 million on a pro forma basis.
  • Other:  Net sales of other products for the third quarter of 2012 were $13.4 million. These products include other non-promoted products acquired in the EUSA Pharma and Azur Pharma transactions. 
  • Other Financial Highlights

  • Cost of product sales increased by $28.7 million compared to the third quarter of 2011 due to higher net sales and $10.3 million of purchase accounting inventory fair value step-up.
  • Selling, general and administrative expenses increased by $30.4 million compared to the prior year quarter, primarily due to increased headcount and related expenses from the addition of the Azur Pharma and EUSA Pharma businesses.
  • Intangible asset amortization for the third quarter of 2012 was $19.7 million, related primarily to the company's expanded product portfolio.
  • Interest expense increased by $7.6 million compared to the third quarter of 2011 due to inclusion of a full quarter's interest under the company's term loan which had a balance of $462.3 million as of September 30, 2012.
  • Recent Transaction and Balance Sheet UpdateOn October 15, 2012, Jazz Pharmaceuticals completed the sale of its women's health business to Meda for $97.6 million in cash, including $2.6 million for certain purchased inventory.  Following this transaction, Jazz Pharmaceuticals has approximately $300 million in cash and cash equivalents.

    2012 Financial GuidanceJazz Pharmaceuticals is providing 2012 guidance for continuing operations which reflects the sale of its women's health business and the treatment of that business as a discontinued operation.  2012 Guidance for
    Continuing OperationsRevenues

    $575-585 millionTotal Net Product Sales$570-580 million-Xyrem Net Sales

    $375-380 million-Erwinaze/Erwinase Net Sales (partial year)1

    $65-69 millionAdjusted Gross Margin %2

    88-91%Adjusted Combined SG&A and R&D Expenses3

    $200-205 millionGAAP Income from Continuing Operations$140-151 millionAdjusted Net Income4

    $280-286 millionGAAP Income from Continuing Operations Per Diluted Share

    $2.34-$2.49Adjusted Net Income Per Diluted Share4

    $4.65-$4.75 

    1.

    Expected sales from and after the completion of the EUSA acquisition on June 12, 2012. 2.

    Excludes $17‑18 million of purchase accounting inventory fair value step-up and $1 million of share‑based compensation expense from estimated GAAP Gross Margin of 85-88%. 3.

    Excludes $22‑24 million of transaction, integration and restructuring costs, $22‑23 million of share‑based compensation expense, and $2 million related to a change in the fair value of contingent consideration from estimated GAAP Combined SG&A and R&D Expenses of $245-250 million. 4.

    See "Non‑GAAP Financial Measures" below. A reconciliation of GAAP to non‑GAAP adjusted 2012 financial guidance is included with this press release.Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EST (9:30 p.m. GMT) to provide a business and financial update and discuss 2012 third quarter results and 2012 guidance.  The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary.  Investors may participate in the conference call by dialing +1 866-783-2137 in the U.S., or +1 857-350-1596 outside the U.S., and entering passcode 22418849.

    An archived version of the webcast will be available for at least one week in the Investors & Media section of the Jazz Pharmaceuticals website a www.jazzpharmaceuticals.com.About Jazz PharmaceuticalsJazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma.

    Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals' financial results and guidance presented on a GAAP basis, the company uses certain non-GAAP adjusted income and adjusted net income financial measures. The company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company during 2012.  They are not meant to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. Jazz Pharmaceuticals' management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Compensation of executives is based in part on the performance of the company's business based on these non-GAAP measures. In addition, Jazz Pharmaceuticals believes that the use of these non-GAAP measures enhances the ability of investors to compare its results from period to period. Adjusted income and adjusted net income financial measures as used by Jazz Pharmaceuticals may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.  The adjusted income from continuing operations and adjusted net income measures used in this press release represent GAAP income from continuing operations excluding revenue related to upfront and milestone payments, amortization of intangible assets, share-based compensation expense, purchase accounting inventory fair value step-up adjustments, transaction and integration costs, restructuring charges, change in fair value of contingent consideration, loss on extinguishment of debt, other non-cash items, and the income tax effects of these adjustments and acquisition restructuring activities. The adjusted income from discontinued operations measures used in this press release represent GAAP loss from discontinued operations excluding amortization of intangible assets, share-based compensation expense and purchase accounting inventory fair value step-up adjustments. 

    This press release also includes, with respect to the company's 2012 financial guidance, the non-GAAP financial measures "adjusted gross margin percentage" and "adjusted combined selling, general and administrative and research and development expenses".  As used in this press release, "adjusted gross margin percentage" and "adjusted combined selling, general and administrative and research and development expenses" exclude from GAAP gross margin percentage and GAAP combined selling, general and administrative and research and development expenses, respectively, as applicable, share-based compensation expense, purchase accounting inventory fair value step-up adjustments, transaction and integration costs, restructuring charges and change in fair value of contingent consideration. The company believes that, similar to the presentation of adjusted net income and adjusted net income per diluted share, these non-GAAP financial measures are also helpful in understanding the company's 2012 financial guidance, particularly in light of the effect of various acquisition and divestiture transactions effected by the company during 2012. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures, and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. 

    "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial results and growth potential, including 2012 financial guidance, future product development and other statements that are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; successfully integrating and growing Jazz Pharmaceuticals' combined business operations after the Azur Pharma merger and EUSA Pharma acquisition, which may be more difficult, time-consuming or costly than expected, particularly in light of the company's expanded international footprint; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and foreign regulatory agencies; dependence on key customers and sole source suppliers; the company's ability to protect intellectual property rights with respect to its products; the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval; and potential restrictions on the company's ability and flexibility to pursue future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and future filings and reports by the company, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.    JAZZ PHARMACEUTICALS PLC  CONDENSED CONSOLIDATED STATEMENTS OF INCOME  (In thousands, except per share amounts)  (Unaudited) Three Months Ended September 30,Nine Months Ended September 30,2012201120122011 Revenues:  Product sales, net 

    $ 174,130$ 72,216$ 398,585$ 185,583 Royalties and contract revenues 

    1,3851,0773,6913,158 Total revenues 

    175,51573,293402,276188,741 Operating expenses:  Cost of product sales 

    32,6293,90152,66210,080 Selling, general and administrative 

    60,92430,547162,50572,552 Research and development 

    6,9203,27913,20010,356 Intangible asset amortization 

    19,7421,86243,4445,586 Total operating expenses 

    120,21539,589271,81198,574 Income from operations 

    55,30033,704130,46590,167 Interest expense, net 

    (7,750)(125)(9,199)(1,559) Foreign exchange and other 

    (1,099)-(1,357)- Loss on extinguishment of debt 

    -(1,097)-(1,097) Income from continuing operations before provision for income tax expense 

    46,45132,482119,90987,511 Provision for income tax expense 

    12,856-24,966- Income from continuing operations 

    33,59532,48294,94387,511 Loss from discontinued operations 

    (386)-(6,908)- Net income$  33,209$ 32,482$  88,035$   87,511Basic income (loss) per share:Income from continuing operations

    $
    .59$
    .77$
    .69$
    2.12Loss from discontinued operations

    (0.01)-(0.12)-Net income

    $
    .58$
    .77$
    .57$
    2.12Diluted income (loss) per share:Income from continuing operations

    $
    .56$
    .69$
    .59$
    .88Loss from discontinued operations

    (0.01)-(0.12)-Net income

    $
    .55$
    .69$
    .47$
    .88 Weighted-average ordinary shares used in per share computations:  Basic 

    57,70342,02856,19841,206 Diluted 

    60,88347,24159,84646,577 JAZZ PHARMACEUTICALS PLC  SUMMARY OF PRODUCT SALES, NET  (In thousands)  (Unaudited) Three Months Ended September 30,Nine Months Ended September 30,2012201120122011Xyrem

    $ 102,615$ 62,547$ 265,149$ 161,503Erwinaze/Erwinase (1)

    31,652-37,660-Prialt (1)

    5,413-20,491-Psychiatry:Luvox CR

    11,6059,66931,63424,080FazaClo LD (1)

    6,370-17,905-FazaClo HD (1)

    3,057-8,979-Other (1)

    13,418-16,767-Total

    $ 174,130$ 72,216$ 398,585$ 185,583(1)

    Net sales for the three and nine months ended September 30, 2012 reported by Jazz Pharmaceuticals plc include net sales from the historic Azur Pharma business for the period from July 1, 2012 through September 30, 2012 and from January 18, 2012 through September 30, 2012, respectively, and net sales from the historic EUSA Pharma business for the period from July 1, 2012 through September 30, 2012 and from June 12, 2012 through September 30, 2012, respectively.
    Net sales from women's health products are included in discontinued operations.The following unaudited pro forma information represents the combined net product sales for the three and nine months ended September 30, 2012 and 2011, respectively, as if the merger with Azur Pharma, the acquisition of EUSA Pharma and disposition of the women's health business had each been completed on January 1, 2011:SUMMARY OF PRODUCT SALES, NET (PRO FORMA) (In thousands) (Unaudited)Three Months Ended September 30,Nine Months Ended September 30,2012201120122011Xyrem

    $ 102,615$ 62,547$ 265,149$ 161,503Erwinaze/Erwinase

    31,6529,63897,44725,686Prialt

    5,4134,98420,83014,827Psychiatry:Luvox CR

    11,6059,66931,63424,080FazaClo LD

    6,3707,71318,13822,015FazaClo HD

    3,0572,3229,1095,538Other

    13,41812,32238,70839,935Total pro forma net sales

    $ 174,130$ 109,195$ 481,015$ 293,584JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited) September 30,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents

    $ 189,793$ 82,076Marketable securities

    -75,822Accounts receivable

    88,30434,374Inventories

    30,3003,909Prepaid expenses

    7,1271,690Other current assets

    9,9421,260Assets held for sale

    59,546-Total current assets

    385,012199,131Property and equipment, net

    6,6711,557Intangible assets, net

    876,95914,585Goodwill

    437,65238,213Other long-term assets

    20,40587Total assets

    $ 1,726,699$ 253,573LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities:Accounts payable

    $ 20,535$ 5,129Accrued liabilities

    123,63234,783Current portion of long-term debt

    26,719-Purchased product rights liability

    5,7434,500Liability under government settlement

    -7,320Deferred revenue

    1,9431,138Total current liabilities

    178,57252,870Deferred revenue, non-current

    7,1297,915Long-term debt, less current portion

    435,631-Contingent consideration

    36,200-Deferred tax liability

    180,919-Other non-current liabilities

    2,161-Total shareholders' equity

    886,087192,788Total liabilities and shareholders' equity

    $ 1,726,699$ 253,573JAZZ PHARMACEUTICALS PLC RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (In thousands, except per share amounts) (Unaudited) Three Months EndedSeptember 30, 2012September 30, 2011GAAPAdjustmentNon-GAAPGAAPAdjustmentNon-GAAPTotal revenues

    $ 175,515$
    -$ 175,515$ 73,293$ (285)

    (g)

    $ 73,008Cost of product sales

    32,629(10,771)

    (a)

    21,8583,901(201)

    (c)

    3,700Selling, general and administrative

    60,924(9,275)

    (b)

    51,64930,547(8,130)

    (h)

    22,417Research and development

    6,920(681)

    (c)

    6,2393,279(838)

    (c)

    2,441Intangible asset amortization

    19,742(19,742)-1,862(1,862)-Interest expense, net

    7,750(1,261)

    (d)

    6,489125-125Loss on extinguishment of debt

    ---1,097(1,097)-Provision for income tax expense

    12,856(3,263)

    (e)

    9,593---Income from continuing operations

    33,59544,99378,58832,48211,84344,325Income (loss) from discontinued operations

    (386)3,372

    (f)

    2,986---Diluted income (loss) per share:Income from continuing operations

    $ 0.56$ 1.29$ 0.69$ 0.94Income (loss) from discontinued operations

    (0.01)0.05--Total

    0.551.340.690.94(a)

    Purchase accounting inventory fair value step-up of $10,336, share-based compensation expense of $344 and restructuring expense of $91.(b)

    Share-based compensation expense of $5,330, restructuring charges of $1,542, transaction and integration costs of $1,503, and change in fair value of contingent consideration of $900.(c)

    Share-based compensation expense.(d)

    Non-cash interest expense primarily associated with debt discount and debt issuance costs.(e)

    Tax related to acquisition restructuring of $9,529 partially offset by the tax effect of non-GAAP pre-tax adjustments of $6,266.(f)

    Intangible asset amortization of $2,009, purchase accounting inventory fair value step-up of $1,106 and share-based compensation expense of $257.(g)

    Revenue related to upfront and milestone payments.(h)

    Transaction and integration costs of $5,974 and share-based compensation expense of $2,156. JAZZ PHARMACEUTICALS PLC RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (In thousands, except per share amounts) (Unaudited) Nine Months EndedSeptember 30, 2012September 30, 2011GAAPAdjustmentNon-GAAPGAAPAdjustmentNon-GAAPTotal revenues

    $ 402,276$
    -$ 402,276$ 188,741$ (854)

    (g)

    $ 187,887Cost of product sales

    52,662(15,766)

    (a)

    36,89610,080(430)

    (c)

    9,650Selling, general and administrative

    162,505(32,848)

    (b)

    129,65772,552(12,960)

    (h)

    59,592Research and development

    13,200(1,718)

    (c)

    11,48210,356(2,342)

    (c)

    8,014Intangible asset amortization

    43,444(43,444)-5,586(5,586)-Interest expense, net

    9,199(1,569)

    (d)

    7,6301,559(394)

    (d)

    1,165Loss on extinguishment of debt

    ---1,097(1,097)-Provision for income tax expense

    24,966(6,160)

    (e)

    18,806---Income from continuing operations

    94,943101,505196,44887,51121,955109,466Income (loss) from discontinued operations

    (6,908)11,185

    (f)

    4,277---Diluted income (loss) per share:Income from continuing operations

    $ 1.59$ 3.28$ 1.88$ 2.35Income (loss) from discontinued operations

    (0.12)0.07--Total

    1.473.351.882.35(a)

    Purchase accounting inventory fair value step-up of $14,676, share-based compensation expense of $999 and restructuring expense of $91.(b)

    Transaction and integration costs of $17,692, share-based compensation expense of $11,967, restructuring charges of $2,089 and change in fair value of contingent consideration of $1,100.(c)

    Share-based compensation expense.(d)

    Non-cash interest expense primarily associated with debt discount and debt issuance costs.(e)

    Tax related to acquisition restructuring of $15,379 partially offset by the tax effect of non-GAAP pre-tax adjustments of $9,219.(f)

    Intangible asset amortization of $7,571, purchase accounting inventory fair value step-up of $3,146 and share-based compensation expense of $468.(g)

    Revenue related to upfront and milestone payments.(h)

    Share-based compensation expense of $6,986 and transaction and integration costs of $5,974. JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED STATEMENTS OF DISCONTINUED OPERATIONS(In thousands)(Unaudited)Three Months Ended September 30, 2012Nine Months Ended September 30, 2012Product sales, net

    $
    8,086$
    9,277Loss from discontinued operations

    $
    (386)$
    (6,908) JAZZ PHARMACEUTICALS PLC  RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2012 FINANCIAL GUIDANCE  (In millions, except per share amounts)  GAAP income from continuing operations 

    $140 - 151 Intangible asset amortization 

    63 Share-based compensation expense 

    23-24 Purchase accounting inventory fair value step-up 

    17 - 18 Transaction, integration and restructuring costs 

    22 - 24 Change in fair value of contingent consideration 

    2 Other non-cash expense 

    3 Income tax adjustments 

    5-6 Adjusted net income 

    $280 - 286 GAAP income from continuing operations per diluted share 

    $2.34 - $2.49 Adjusted net income per diluted share 

    $4.65 - $4.75 Shares used in computing per diluted share amounts 

    60
    '/>"/>

    SOURCE Jazz Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
    2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
    3. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
    4. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
    5. Genoa Pharmaceuticals announces $1.2M Financing
    6. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
    7. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
    8. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
    9. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
    10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    11. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
    (Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
    (Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
    (Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
    (Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
    Breaking Medicine News(10 mins):